Evidence map›Paper›PMID 41098563›Full record

ArticleACS pharmacology & translational science2025

LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting.

Antonella Rocchi, Valeria Sidorenko, Nicola d'Avanzo, Luca Marchetti, Jhalak Sethi, Luigi Ciriolo, Anna Maria Tolomeo, Maria Grazia Cifone, Paola Palumbo, Massimo Fresta and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonella RocchiLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia.ORCID https://orcid.org/0009-0003-3949-0772
Valeria SidorenkoLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia.
Nicola d'AvanzoDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", V.le "S. Venuta", Catanzaro I-88100, Italy.
Luca MarchettiLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia.
Jhalak SethiLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia.
Luigi CirioloDepartment of Health Science, University of Catanzaro "Magna Græcia", V.le "S. Venuta", Catanzaro I-88100, Italy.
Anna Maria TolomeoDepartment of Cardiac, Thoracic and Vascular Science and Public Health, University of Padova, Padua I-35128, Italy.
Maria Grazia CifoneDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, L'Aquila I-67100, Italy.
Paola PalumboDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, L'Aquila I-67100, Italy.
Massimo FrestaResearch Center "ProHealth Translational Hub", Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Campus Universitario "S. Venuta" - Building of BioSciences, Viale S. Venuta, Catanzaro I-88100, Italy.ORCID https://orcid.org/0000-0001-8062-817X
Tambet TeesaluLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia.
Christian CeliaDepartment of Pharmacy, University of Chieti - Pescara "G. d'Annunzio", Via dei Vestini 31, Chieti 66100, Italy.ORCID https://orcid.org/0000-0002-0590-5429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited therapeutic options and a poor prognosis. We developed hybrid lipid-polymer nanoparticles (HLPNs) functionalized with tumor-homing C-end Rule peptide LinTT1 (LinTT1-HLPNs) to improve the GBM targeting.

Indexed as

CendR peptideglioblastoma multiformehybrid nanoparticlesnanomedicineprecision medicinetumor homing peptides

Identifiers

PMID41098563
PMCPMC12519261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.